Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 8NETWORK 7NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Arthritis, Rheumatoid 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Graft vs Host Disease 6Leukemia 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Lymphoma, Follicular 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Psoriasis 2Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Stomatitis 1Recurrence 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neutropenia 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Lymphoproliferative Disorders 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Methotrexate × Clear all
NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

AstraZeneca

Phase 3 Recruiting
150 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡